Cipher Pharmaceuticals (TSE:CPH) Hits New 1-Year Low – Here’s What Happened

Shares of Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR) hit a new 52-week low on Tuesday. The company traded as low as C$13.37 and last traded at C$13.27, with a volume of 10,398 shares changing hands. The stock had previously closed at C$13.40.

Cipher Pharmaceuticals Trading Down 0.8%

The company has a debt-to-equity ratio of 0.44, a current ratio of 1.99 and a quick ratio of 2.67. The company has a market cap of C$337.77 million, a price-to-earnings ratio of 11.87 and a beta of 1.29. The business’s 50-day simple moving average is C$13.74 and its 200-day simple moving average is C$15.72.

Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last released its earnings results on Thursday, November 12th. The company reported C$0.60 earnings per share (EPS) for the quarter. Cipher Pharmaceuticals had a net margin of 69.98% and a return on equity of 25.48%. The company had revenue of C$18.08 million for the quarter. Research analysts predict that Cipher Pharmaceuticals Inc. will post 1.29 earnings per share for the current fiscal year.

Insider Activity at Cipher Pharmaceuticals

In related news, Director Craig Mull bought 20,000 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was bought at an average price of C$14.16 per share, with a total value of C$283,200.00. Following the completion of the transaction, the director directly owned 1,009,953 shares of the company’s stock, valued at approximately C$14,300,934.48. This represents a 2.02% increase in their ownership of the stock. 42.00% of the stock is currently owned by corporate insiders.

Cipher Pharmaceuticals Company Profile

(Get Free Report)

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.

See Also

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.